Café

© 2026 Longbridge｜Terms of Service Privacy Policy

BIO-THERA

688177

17.110.18% ( +0.03 )

Delay Closed: Jul 31, 15:00:00

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
WorldPharmaceuticals·Jul 24 at 04:10 AM
688177+0.18%
China's Bio-Thera Gets US Nod for Golimumab Biosimilar
Yicai·May 19 at 03:45 AM
688177+0.18%
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
PR Newswire·May 18 at 07:00 AM
688177+0.18%
Baili Tianheng's iza-bren late-stage triple-negative breast cancer Phase III clinical study achieved dual endpoints of PFS and OS
Wallstreetcn·Feb 23 at 03:01 AM
688177+0.18%
05:33 ET Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
prnewswire·Dec 12, 2025 at 04:34 AM
688177+0.18%
BIO-THERA released its performance for the first three quarters, with a net loss attributable to the parent company of 224 million yuan
Zhitong·Oct 28, 2025 at 08:07 AM
688177+0.18%
Eli Lilly FRα ADC launches Phase III clinical study
Zhitong·Oct 10, 2025 at 07:58 AM
LLY-0.53%688177+0.18%
Bio-Thera, Intas extend partnership for golimumab biosimilar
Pharmaceutical Business Review·Oct 10, 2025 at 06:37 AM
688177+0.18%
BIO-THERA: Qletli® (Adalimumab Injection) has received marketing authorization from the UK MHRA
Zhitong·Sep 10, 2025 at 03:19 AM
688177+0.18%
BIO-Thera, STADA expand biosimilars partnership to include tocilizumab
WorldPharmaceuticals·Aug 25, 2025 at 03:53 AM
688177+0.18%
Bio-Thera Solutions, STADA To Extend Biosimilars Alliance To Cover Tocilizumab
rttnews·Aug 22, 2025 at 07:28 AM
688177+0.18%
Bio-Thera and STADA will collaborate on biosimilar tocilizumab for treating inflammatory disorders.
Unusual Whales·Aug 22, 2025 at 07:04 AM
688177+0.18%
BIO-THERA has signed a licensing and commercialization agreement with STADA for BAT1806 (Tocilizumab) injection
Zhitong·Aug 20, 2025 at 07:36 PM
688177+0.18%